HYDERABAD: Biopharma major Biological E has inked a commercial supply agreement with Dynavax Technologies Corporation for the use of the US-based company’s advanced adjuvant CpG 1018 in its subunit Covid-19 vaccine candidate — Corbevax.
Biological E said the commercial supply agreement will extend through 2022 and also includes doses for delivery in 2021 that were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax.
The company also said it expects to launch Corbevax later this year subject to conditional regulatory approvals from the Indian drug regulator. The Union health ministry has already reserved 300 million doses of Corbevax in June this year at an advance payment of Rs 1,500 crore. Corbevax doses to be supplied to Indian government will be manufactured later this year, Bio E said.
“Dynavax is proud to extend our collaboration with Biological E with a commercial supply agreement and deliver significant amounts of CpG 1018 in hopes that Corbevax will be an important Covid-19 vaccine protecting people globally regardless of income level,” said Dynavax CEO Ryan Spencer.
Bio E managing director Mahima Datla, said: “Our collaboration will produce yet another vital vaccine against the spread of Covid-19. We believe Corbevax will play a critical role in eradicating the global pandemic.” CpG 1018 is already being used in Dynavax’s recombinant Hepatitis-B vaccine Heplisav-B, which is an adult vaccine approved by US FDA and European Commission. Bio E develops, manufactures and supplies vaccines to over 100 countries, and currently has eight WHO-prequalified vaccines in its portfolio.
.jpg?w=600)
